January 16, 2024 Licensing, IP, and Legal

European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types

Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5 Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6 Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as... Read more

January 9, 2024 Environ, Ag./Food & Bev Lab Top-10 PAI Top-10

Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution

Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devastating illnesses Innovative model... Read more

January 4, 2024 Bio/Pharma/CRO Lab Top-10 Liq. Handling & Robotics Microscopy

Bruker Announces Acquisition of Tornado Spectral Systems to Expand Its Biopharma Process Analytical Technology (PAT) Product Portfolio

Bruker Announces Acquisition of Tornado Spectral Systems to Expand Its Biopharma Process Analytical Technology (PAT) Product Portfolio MISSISSAUGA, Ontario–(BUSINESS WIRE)– Bruker (Nasdaq: BRKR) today announced the acquisition of Tornado Spectral Systems Inc., a Canadian company specializing in process Raman instruments, primarily used in pharma and biotech quality control applications. Tornado, with over a decade of... Read more

January 3, 2024 Lab Top-10

Bruker Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Bruker Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 42nd annual J.P. Morgan Healthcare Conference in San Francisco. Frank Laukien, Chairman, President & CEO, Mark Munch, Executive Vice President & President of Bruker Nano Group, and Gerald Herman,... Read more

January 3, 2024 Lab Top-10

Thermo Fisher Scientific to Present at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024

Thermo Fisher Scientific to Present at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January... Read more

January 3, 2024 Lab Top-10 Microscopy

Bruker Acquires Electron Microscopy Company Nion

High-end STEM Technology Expands Bruker’s Portfolio for Materials Science Research BILLERICA, Mass.–(BUSINESS WIRE)– Bruker today announced that it has acquired Nion, a privately-held company that develops and manufactures innovative high-end scanning transmission electron microscopes (STEM). Nion was the first company to introduce aberration correction for STEM instruments with ultra-high stability for highest resolution images, and... Read more

January 2, 2024 Lab Top-10 Life Science Tools

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, January 31, 2024

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, January 31, 2024 WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2023 before the market opens on Wednesday, January 31, 2024, and will... Read more

December 29, 2023 Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships

Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform

The transformative point of care solution will complement Roche’s centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease areas LumiraDx’s technology integrates multiple Point of Care tests on a simple to use single instrument and brings more affordable and accessible testing to patients worldwide Under the terms of the agreement,... Read more